Anthos Therapeutics is a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for high-risk cardiovascular patients.

Anthos is a formation of Blackstone (NYSE: BX) Life Sciences and Novartis AG (NYSE: NVS), one of the worlds’ leading pharmaceutical companies. The company is led by a world-class executive team highly experienced in the successful development of therapies for cardiovascular disease.